NEW YORK--(BUSINESS WIRE)--Jun 30, 2009 - Pfizer Inc announced today the discontinuation of the SUN 1122 Phase 3 trial that evaluated Sutent® (sunitinib malate) plus FOLFIRI (irinotecan plus infusional 5-fluorouracil and leucovorin) versus...


June 30, 2009 | Filed Under News
Comments